Pregnant women who received financial incentives to refrain from smoking during late pregnancy were more successful at remaining abstinent and less likely to have babies with low birth weight, according to data from three trials.
Patients were more likely to take a rapid HIV test when substance abuse treatment programs offered the test onsite rather than referred for offsite testing. Patients were equally likely to accept and learn their HIV status whether the offer of onsite testing was accompanied by 30 minutes of risk reduction counseling or by 5 minutes of brief information on the testing procedure. Onsite testing accompanied by brief information was cost effective, taking into account the projected lifetime costs of treatment and the gains in health and longevity for detected cases.
Dr. Thomas Kosten of Baylor College of Medicine and Dr. Peter Burkhard of the University of Connecticut are the recipients of NIDA’s 2011 Avant-Garde Awards for Innovative Medication Development Research. Dr. Kosten is developing a vaccine against methamphetamine abuse and Dr. Burkhard is developing a vaccine to counter nicotine addiction.
A trial of buprenorphine/naloxone (Bup/Nx) showed no evidence that the medicine was associated with liver damage. The drug gave results similar to those of methadone. The study data indicate that although most patients can be treated safely with either methadone or Bup/Nx without major concern for liver injury, clinicians are advised to continue to monitor the liver health of their patients who are on methadone or Bup/Nx therapy.
July 2011 Discusses research that compares multiple sessions of motivational and behavioral training with that of a single intervention among male and female substance abusers to reduce high-risk sexual behaviors.